Cinctive Capital Management LP Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Cinctive Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$110.08 - $142.92 $1.92 Million - $2.5 Million	-17,462 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $1.74 Million - $2.59 Million	17,462 New	17,462 $2.41 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $6.88 Million - $9.67 Million	-69,614 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$65.78 - $105.02 $1.37 Million - $2.19 Million	-20,836 Reduced 23.04%	69,614 $6.76 Million
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $5.8 Million - $8.3 Million	90,450 New	90,450 $6.18 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $1.58 Million - $2.38 Million	-24,270 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$59.04 - $77.95 $1.43 Million - $1.89 Million	24,270 New	24,270 $1.58 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Cinctive Capital Management LP with notifications on news.